AUTHOR=Naseralallah Lina , Khatib Malkan , Al-Khulaifi Azhar , Danjuma Mohammed 

TITLE=Prevalence and global trends of polypharmacy in patients with chronic kidney disease: A systematic review and meta-analysis

JOURNAL=Frontiers in Pharmacology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1122898

DOI=10.3389/fphar.2023.1122898

ISSN=1663-9812

ABSTRACT=<p><bold>Background and objectives:</bold> Polypharmacy and chronic kidney disease (CKD) are becoming increasingly common due to an ageing population and the rise of multimorbidity. In line with the therapeutic guidelines, managing CKD and its complications necessitates prescribing multiple medications, which predisposes patients to polypharmacy. The aim of this systematic review and meta-analysis is to describe the prevalence of polypharmacy in patients with CKD and to explore the global trends of factors driving any apparent variability in prevalence estimates.</p><p><bold>Methods:</bold> PubMed, Scopus, the Cochrane Database of Systematic Reviews (CDSR), and Google Scholar were searched from 1999 to November 2021. Study selection, data extraction, and critical appraisal were conducted by two independent reviewers. The pooled prevalence of polypharmacy was estimated utilizing the random effects model using the default double arcsine transformation.</p><p><bold>Results:</bold> This review involved 14 studies comprising of 17 201 participants, a significant proportion of which were males (56.12%). The mean age of the review population was 61.96 (SD ± 11.51) years. The overall pooled prevalence of polypharmacy amongst patients with CKD was 69% (95% CI: 49%–86%) (I<sup>2</sup> = 100%, <italic>p</italic> &lt; 0.0001), with a proportionately higher prevalence in North America and Europe as compared to Asia.</p><p><bold>Conclusion:</bold> The results from this meta-analysis showed a high pooled prevalence estimates of polypharmacy amongst patient cohorts with CKD. The exact interventions that are likely to significantly mitigate its effect remain uncertain and will need exploration by future prospective and systematic studies.</p><p><bold>Systematic Review Registration</bold>: [<ext-link ext-link-type="uri" xlink:href="https://www.crd.york.ac.uk/prospero/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.crd.york.ac.uk/prospero/</ext-link>], identifier [CRD42022306572].</p>